Circulating tumor DNA (ctDNA) and exosomal RNA can provide dynamic, non-invasive insights into tumor evolution and immune evasion pathways, such as acquired mutations in β2-microglobulin or JAK1/2, which are associated with resistance to immune checkpoint inhibitors [4,46]. This evidence concerns the gene JAK1 and neoplasm.